Related Experiment Video
Updated: Jun 21, 2026
12:05
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
Autoimmune Features in Myelodysplastic Syndromes: Clinical and Molecular Heterogeneity With Integrated IPSS-M
1Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Clinical Lymphoma, Myeloma & Leukemia
|June 19, 2026
Summary
Autoimmune features in myelodysplastic syndromes (MDS) show varied clinical and molecular traits. However, only the International Prognostic Scoring System-Mutation (IPSS-M) score, not autoimmunity, independently impacts patient survival.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Autoimmune features are increasingly recognized in myelodysplastic syndromes (MDS).
- The clinical and molecular significance of these autoimmune features in MDS remains unclear.
- This study aimed to characterize MDS based on autoimmune status.
Purpose of the Study:
- To investigate the clinicopathologic, cytogenetic, molecular, and prognostic differences in myelodysplastic syndromes (MDS) with and without autoimmune features.
- To compare clinical characteristics, genomic alterations, and survival outcomes among different groups of MDS patients based on autoimmunity.
Main Methods:
- Retrospective analysis of 163 newly diagnosed myelodysplastic syndromes (MDS) patients.
- Classification into three groups: MDS with autoimmune disease (MDS-AID), MDS with laboratory evidence of autoimmunity only (MDS-ALE), and MDS without autoimmune features (MDS-control).
- Comparison of clinical data, genetic mutations, and survival outcomes using statistical analyses, including Cox proportional hazards models and multivariable analyses.
Main Results:
- MDS-AID patients were younger, more often female, and had lower-risk MDS with fewer mutations compared to MDS-control.
- Trisomy 8 and 9 were more frequent in lower-risk MDS-AID, while ASXL1 mutations were increased in MDS-ALE.
- No significant differences in overall or progression-free survival were observed between MDS with autoimmune features (MDS-AID, MDS-ALE) and MDS-control.
- The International Prognostic Scoring System-Mutation (IPSS-M) score was the sole independent predictor of survival in multivariable analyses.
Conclusions:
- Myelodysplastic syndromes (MDS) with autoimmune features display significant clinical and molecular heterogeneity.
- Autoimmune status itself is not an independent prognostic factor for survival in MDS.
- The IPSS-M score remains the critical determinant of survival outcomes in MDS patients, irrespective of autoimmune features.
More Related Videos
Related Concept Videos
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
01:21EPS and iPS Cells in Disease Research
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...